Department of Pediatrics, Örebro University Hospital, Örebro, Sweden.
Faculty of Health and Medicine, Örebro University, Örebro, Sweden.
BMC Nephrol. 2021 May 5;22(1):165. doi: 10.1186/s12882-021-02353-7.
Chronic kidney disease has been linked to cardiovascular disease and specifically ischemic heart disease (IHD), but large-scale population data in patients with immunoglobulin A nephropathy (IgAN) are missing.
To examine absolute and relative risks for IHD in patients with IgAN.
Population-based register-based cohort study in Sweden. We identified 3945 patients with biopsy-verified IgAN, and 19,272 age- and sex-matched reference individuals from the general population. To reduce residual confounding from genetic factors and early environmental factors we carried out secondary analyses, where we compared 3039 IgAN patients with 6729 siblings, whereas a spousal analysis consisted of 2377 married couples where one of the spouses had IgAN. Data on IHD and end-stage renal disease (ESRD) were retrieved from the nationwide Patient Register. Cox regression estimated hazard ratios (HRs) adjusted for matching variables, education, country of birth, cancer, diabetes mellitus, and other systemic inflammatory diseases.
During a follow-up of 55,527 person-years (py; mean follow-up 14.1 years), 371 patients (9.4%) with IgAN developed IHD (6.7/1000 py), compared with 1070 (5.6%) in 287,677 py in reference individuals (3.7/1000 py). The corresponding adjusted HR was 1.86 (95%CI = 1.63-2.13), equivalent to one extra case of IHD per 34 IgAN patients followed-up for 10 years. HRs were similar in men and women with IgAN, but higher in the first year after diagnosis and in patients born outside the Nordic countries. Patients with IgAN were at increased risk of IHD also compared to siblings (HR = 2.07; 95%CI = 1.62-2-64) and spouses (HR = 1.91; 95%CI = 1.40-2.61).
In this nationwide population-based study, patients with IgAN were at an 86% increased risk of future IHD.
慢性肾脏病与心血管疾病,特别是缺血性心脏病(IHD)有关,但在 IgA 肾病(IgAN)患者中缺乏大规模的人群数据。
检查 IgAN 患者发生 IHD 的绝对风险和相对风险。
这是一项在瑞典进行的基于人群的登记队列研究。我们确定了 3945 名经活检证实的 IgAN 患者,以及 19272 名来自普通人群的年龄和性别匹配的参考个体。为了减少遗传因素和早期环境因素造成的残余混杂,我们进行了二次分析,其中将 3039 名 IgAN 患者与 6729 名兄弟姐妹进行了比较,而配偶分析则包括 2377 对已婚夫妇,其中一方患有 IgAN。IHD 和终末期肾病(ESRD)的数据从全国性的患者登记处获取。Cox 回归估计了调整匹配变量、教育、出生国、癌症、糖尿病和其他全身性炎症性疾病后的风险比(HRs)。
在 55527 人年的随访中(平均随访 14.1 年),371 名(9.4%)IgAN 患者发生了 IHD(6.7/1000 人年),而在 287677 人年的参考个体中,有 1070 名(5.6%)发生了 IHD(3.7/1000 人年)。相应的调整 HR 为 1.86(95%CI=1.63-2.13),相当于每 34 名接受 10 年随访的 IgAN 患者中就有 1 例额外发生 IHD。IgAN 患者的 HR 在男性和女性中相似,但在诊断后的第一年和在北欧国家以外出生的患者中较高。与兄弟姐妹(HR=2.07;95%CI=1.62-2.64)和配偶(HR=1.91;95%CI=1.40-2.61)相比,IgAN 患者发生 IHD 的风险也更高。
在这项全国范围内的基于人群的研究中,IgAN 患者未来发生 IHD 的风险增加了 86%。